Show simple item record

dc.contributor.authorForbes, Ian T.
dc.contributor.authorCooper, David G.
dc.contributor.authorDodds, Emma K.
dc.contributor.authorHickey, Deirdre M. B.
dc.contributor.authorIfe, Robert J.
dc.contributor.authorMeeson, Malcolm
dc.contributor.authorStockley, Martin
dc.contributor.authorBerkhout, Theo
dc.contributor.authorGohil, Jayneeta
dc.contributor.authorGroot, Pieter H. E.
dc.contributor.authorMoores, Kitty E.
dc.identifier.citationForbes , I T , Cooper , D G , Dodds , E K , Hickey , D M B , Ife , R J , Meeson , M , Stockley , M , Berkhout , T , Gohil , J , Groot , P H E & Moores , K E 2000 , ' CCR2B receptor antagonists : Conversion of a weak HTS hit to a potent lead compound ' , Bioorganic and Medicinal Chemistry Letters , vol. 10 , no. 16 , pp. 1803-1806 .
dc.identifier.otherPURE: 7129741
dc.identifier.otherPURE UUID: 84bfec09-b8f6-42bc-8d0d-3530c017eb54
dc.identifier.otherScopus: 0034698896
dc.identifier.otherPubMed: 10969972
dc.description.abstractA weak HTS hit at the CCR2B receptor has been converted into a potent antagonist by array SAR studies. Selectivity over the closely related CCR5 receptor is also achieved. (C) 2000 Elsevier Science Ltd. All rights reserved.en
dc.relation.ispartofBioorganic and Medicinal Chemistry Letters
dc.subjectMolecular Biology
dc.subjectOrganic Chemistry
dc.subjectDrug Discovery
dc.subjectPharmaceutical Science
dc.titleCCR2B receptor antagonists : Conversion of a weak HTS hit to a potent lead compounden
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionMedicinal and Analytical Chemistry
dc.description.statusPeer reviewed
rioxxterms.typeJournal Article/Review

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record